- Home
- RNAZ vs BMRA Comparison
RNAZ vs BMRA Comparison
Compare RNAZ & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- BMRA
- Stock Information
- Founded
- RNAZ 2016
- BMRA 1971
- Country
- RNAZ United States
- BMRA United States
- Employees
- RNAZ N/A
- BMRA N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- RNAZ Health Care
- BMRA Health Care
- Exchange
- RNAZ Nasdaq
- BMRA Nasdaq
- Market Cap
- RNAZ 8.7M
- BMRA 8.2M
- IPO Year
- RNAZ 2021
- BMRA N/A
- Fundamental
- Price
- RNAZ $14.80
- BMRA N/A
- Analyst Decision
- RNAZ Strong Buy
- BMRA
- Analyst Count
- RNAZ 1
- BMRA 0
- Target Price
- RNAZ $280.00
- BMRA N/A
- AVG Volume (30 Days)
- RNAZ 387.0K
- BMRA 33.1K
- Earning Date
- RNAZ 11-13-2025
- BMRA 10-10-2025
- Dividend Yield
- RNAZ N/A
- BMRA N/A
- EPS Growth
- RNAZ N/A
- BMRA N/A
- EPS
- RNAZ N/A
- BMRA N/A
- Revenue
- RNAZ N/A
- BMRA $5,311,000.00
- Revenue This Year
- RNAZ N/A
- BMRA N/A
- Revenue Next Year
- RNAZ N/A
- BMRA N/A
- P/E Ratio
- RNAZ N/A
- BMRA N/A
- Revenue Growth
- RNAZ N/A
- BMRA N/A
- 52 Week Low
- RNAZ $6.15
- BMRA $2.08
- 52 Week High
- RNAZ $739.20
- BMRA $10.16
- Technical
- Relative Strength Index (RSI)
- RNAZ 84.37
- BMRA 45.61
- Support Level
- RNAZ $10.32
- BMRA $2.68
- Resistance Level
- RNAZ $12.28
- BMRA $2.83
- Average True Range (ATR)
- RNAZ 0.87
- BMRA 0.11
- MACD
- RNAZ 0.57
- BMRA 0.01
- Stochastic Oscillator
- RNAZ 91.34
- BMRA 54.84
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.